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Coleus  forskohlii  extract  (CFE),  an herbal  ingredient,  is used  for weight-loss  products.  CFE’s
alleged  efﬁcacy  is attributed  to  forskolin.  However,  CFE  has  been  shown  to  induce  fatty
liver  in  mice,  with  components  other  than  forskolin  playing  a  part  in  this  effect.  The  present
study  addressed  the  underlying  mechanism  of  CFE-induced  fatty  liver  by  analyzing  changes
in CFE-treated  mice  of  lipid  concentrations  and of the  levels  of  mRNAs  encoding  enzymes
and  transcription  factors  known  to  be  related  to fatty  liver.  Mice  were  fed a  diet  contain-
ing 0,  0.3  and 1%  CFE  for  2 weeks.  CFE  at 1% clearly  induced  fatty  liver, as  demonstrated
by  histological  examination  and  conﬁrmed  by increases  in  triglyceride  concentrations  in
liver. However,  treated  mice  did  not  exhibit  elevation  in  plasma  levels  of non-esteriﬁed
fatty  acids.  Comprehensive  analysis  of  liver  mRNA  levels  revealed  accumulation  of multi-
ple transcripts,  including  mRNAs  encoding  enzymes  acetyl-CoA  carboxylase  and  long-chain
elongase;  transcription  factor  peroxisome  proliferator-activated  receptor  gamma  (PPAR);ietary  supplement and lipid-droplet-associated  fat-speciﬁc  protein  27  (Fsp27).  These  ﬁndings  suggest  that
the de novo  synthesis  and accumulation  of triglyceride  in  the  liver,  through  the  enhanced
expression  of  speciﬁc  lipogenic  mRNAs,  is a major  underlying  mechanism  of fatty  liver
induction  by CFE.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Obesity is an ongoing concern in the developed world,
ecause this condition increases the risk of chronic diseases
uch  as diabetes mellitus and cardiovascular disease [1].
o  ﬁght obesity, weight-loss dietary supplements often are
sed  without adequate clinical evidence [2]. Among dietary
upplements, herbal products are increasingly used [3], and
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214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open
http://creativecommons.org/licenses/by-nc-nd/3.0/).are sometimes perceived as safe because such supplements
are “natural”. However, recent studies have suggested
that herbal products, especially those used for weight
loss, can cause adverse events such as serious hepatic
failure [4].
Coleus forskohlii extract (CFE) has been used for cen-
turies in Ayurvedic medicine to treat various diseases of the
cardiovascular, respiratory, gastrointestinal, and central
nervous systems [5]. Currently, CFE has received attention
as  a popular herbal ingredient for weight-loss products,
because CFE contains a diterpene compound, forskolin. This
compound  has been shown to activate adenylate cyclase
[6,7]  to enhance lipolysis and fat loss in studies performed
in  cell culture [8,9], rat [10], and human [11,12]. Based on
 access article under the CC BY-NC-ND license
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the activity of this component, CFE is generally standard-
ized at 10% forskolin for use in dietary supplements.
In our previous studies, we observed that CFE induced
hepatic cytochrome P450 (CYP) while also inducing fatty
liver  in mice, although these induction events were not
seen  with forskolin alone [13,14]. The substance that
induced fatty liver and hepatic CYP induction was  soluble
in  ether and ethyl acetate [15]. CYP was induced by CFE
at  a dose lower than that needed to induce fatty liver, but
both  phenomena (CYP and fatty liver) seemed to be related.
CFE-mediated CYP induction was clearly detected in high-
carbohydrate diet [16]. To conﬁrm the safety of CFE as a
dietary  supplement, we sought to examine the mechanism
of  action of CFE in the induction of fatty liver.
The development of fatty liver has been attributed to
increased release of non-esteriﬁed fatty acids from adipose
tissue;  increased de novo synthesis of fatty acids; decreased
beta-oxidation [17]; and decreased export of triglyceride as
lipoprotein  from liver [18].
In the present study, we examined the possible mech-
anism of action of CFE on fatty liver in mice by evaluating
changes in lipid concentrations in plasma and liver, along
with  comprehensive proﬁling of hepatic mRNA expression
of  genes coding for lipogenic and triglyceride synthesis
enzymes, transcription factors, and nuclear receptors.
2.  Materials and method
2.1.  Materials
Powdered CFE standardized to contain 10% forskolin
was prepared as follows. Dried roots of C. forskohlii were
obtained from the Bangalore in southern India, crushed,
and subjected to extraction with supercritical CO2. The
resulting forskolin-rich extract (20–30%) was combined
with dextrin to yield a powder containing 10% forskolin.
These extraction and preparation steps were outsourced
to  Tokiwa Phytochemical Co., Ltd. (Chiba, Japan). The ﬁnal
composition of the resulting CFE powder was as follows:
water, 5.6%; protein, 0.3%; lipids, 22.7%; ash, 2.2%; and car-
bohydrates, 69.2%. The HPLC chromatographic proﬁle has
been  reported elsewhere [19], and the analyzed contents of
forskolin  and 1,9-dideoxyforskolin, two substances avail-
able  as standards in the CFE sample, were 10.37% and 1.71%,
respectively. CFE was added in the proportions described
below to an AIN93G puriﬁed diet purchased from Oriental
Yeast  Co., Ltd. (Tokyo, Japan). All other reagents were pur-
chased  from Wako Pure Chemical Industries, Ltd. (Osaka,
Japan).
2.2.  Animal experiment
Male  ICR mice, aged 5 weeks (CLEA Japan, Inc., Tokyo,
Japan), were housed in polypropylene cages at a constant
temperature (22 ± 1 ◦C) with a 12-h/12-h light-dark cycle.
After  acclimation for 1 week, mice were allocated into three
groups  (5 mice per group), and provided with ad libitum
access to AIN93G puriﬁed diet without CFE (0% CFE; con-
trol)  or supplemented to 0.3% CFE or 1% CFE. After two
weeks on the respective diet, animals were anesthetized
with pentobarbital and exsanguinated from inferior venaports 1 (2014) 787–794
cava  with heparin as an anticoagulant. Livers were imme-
diately removed, weighed, and assessed as follows. For
all  animals, a portion of the liver was stored in RNAlater
(Applied Biosystems, Inc., Foster City, CA, USA) pending
processing for mRNA analysis. For a subset of the animals,
portions of the livers were ﬁxed in 10% neutral buffered
formalin pending processing for histopathological analy-
sis.  Other samples were snap frozen on dry ice and stored
at  −80 ◦C until analysis. All animal procedures were con-
ducted in accordance with the Japan National Institute of
Health  and Nutrition Guidelines for the Care and Use of Lab-
oratory  Animals, and were approved by ethical committee
of  the Japan National Institute of Health and Nutrition.
2.3. Analysis of mRNA levels
Real time RT-PCR experiments were performed by
the  method previously described [20]. Brieﬂy, total RNA
was  extracted using a QuickGene RNA tissue kit SII (Fuji
Photo  Film Co., Ltd., Tokyo, Japan), and the samples were
subjected to real time RT-PCR using the One-Step SYBR RT-
PCR  kit (Perfect Real Time; Takara Bio Inc., Shiga, Japan)
according to the manufacturer’s protocol and Mx3000P®
(STRATAGENE Co., La Jolla, CA, USA). The results were
expressed as copy number ratio of the target mRNA to
that  of cyclophilin mRNA. The speciﬁc primers were syn-
thesized via the Perfect Real Time Primer support system
of  Takara Bio (http://www.takara-bio.co.jp/prt/intro.htm);
primer  sequences are shown in Table 1. The mRNAs ana-
lyzed  in the present study included transcripts encoding
glycolytic enzymes Gck, Gapdh, Pklr1 and Pklr2; lipo-
genesis enzymes Acly, ACC1, ACC2, and Fasn; fatty acid
elongation and desaturation enzymes Elovl6 and Scd1;
triglyceride synthesis enzymes Gpam, Dgat1, and Dgat2;
transcription factor and nuclear receptor proteins ChREBP,
Srebp1, Nr1h2, Nr1h3, and PPAR, PPAR, and PPAR; and
Cidea,  Cideb, Cidec/Fsp27 [21].
2.4. Other measurements
Liver  samples ﬁxed with formalin were embedded in
parafﬁn using standard procedures. The samples were sec-
tioned  at 3-m thicknesses for staining with hematoxylin
and eosin (H&E), or sectioned at 10-m thicknesses for
staining with Oil Red O. These morphological analyses were
outsourced to Biosafety Research Center, Foods, Drugs and
Pesticides  (An-Pyo Center), Shizuoka, Japan. Measurement
of plasma enzyme activities indicative of hepatic failure
was  outsourced to SRL Inc., Tokyo, Japan. The analyzed
activities were alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and alkaline phosphatase (ALP).
Hepatic lipids were extracted by the methods of Bligh
and  Dyer [22]. Concentrations of triglyceride, cholesterol,
phospholipid, and non-esteriﬁed fatty acid were measured
using  test kits from Wako Pure Chemical Industries, Ltd.,
Osaka  Japan.2.5.  Statistical analyses
The  data are presented as the mean and standard error
(SE)  for the individual groups. Statistical analysis of the data
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Table 1
Sequences of primers used for real-time RT-PCR analysis (5′–3′).
Encoded protein Forward Reverse
Cyclophilin ACGCCACTGTCGCTTTTC CTGCAAACAGCTCGAAGGA
Gck CTGGATGACAGAGCCAGGAT CTCTGCCAGGATCTGCTCTAC
Gapdh TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG
Pklr1 ACTTAGCAAAGTCTGCTTTAAGTGG TGGCACGTCTCAGGTATCC
Pklr2 GTGGAGGCTTCCTTCAAGTG AGGTCGGTAGCGAGACAGAA
Acly GCCCTGGAAGTGGAGAAGAT CCGTCCACATTCAGGATAAGA
ACC1 GCGTCGGGTAGATCCAGTT CTCAGTGGGGCTTAGCTCTG
ACC2 TGAATCTCACGCGCCTACTA GCCTCTCTTCACCAGATGGA
Fasn GCTGCTGTTGGAAGTCAGC AGTGTTCGTTCCTCGGAGTG
Elovl6 CAGCAAAGCACCCGAACTA AGGAGCACAGTGATGTGGTG
Scd1 TTCCCTCCTGCAAGCTCTAC CAGAGCGCTGGTCATGTAGT
Gpam GGAAGGTGCTGCTATTCCTG TGGGATACTGGGGTTGAAAA
Dgat1 TCGTGGTATCCTGAATTGGTG AGGTTCTCTAAAAATAACCTTGCATT
Dgat2 GGCGCTACTTCCGAGACTAC TGGTCAGCAGGTTGTGTGTC
ChREBP GGCCTGGCTGGAACAGTA CGAAGGGAATTCAGGACAGT
Srebf1 GGTTTTGAACGACATCGAAGA CGGGAAGTCACTGTCTTGGT
Nr1h2 GCTCTGCCTACATCGTGGTC CTCATGGCCCAGCATCTT
Nr1h3 TGTGCGCTCAGCTCTTGT TGGAGCCCTGGACATTACC
Ppara CTGAGACCCTCGGGGAAC AAACGTCAGTTCACAGGGAAG
Pparg GAAAGACAACGGACAAATCACC GGGGGTGATATGTTTGAACTTG
Ppard ATGGGGGACCAGAACACAC GGAGGAATTCTGGGAGAGGT
Cidea AAACCATGACCGAAGTAGCC AGGCCAGTTGTGATGACTAAGAC
Cideb CTGCCAGCCTCCAAGAACT TAGCACTCCACGTAGCAGCA
Cidec GATGGACTACGCCATGAAGTC GTGCTCACTGCCACATGC
Protein product abbreviations: Gck, glucokinase; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; Pklr1 and Pklr2, pyruvate kinase liver and red blood
cell (Pklr) 1 and 2; Acly, ATP-citrate synthase; ACC1 and ACC2, acetyl-coenzyme A carboxylase 1 and 2; Fasn, fatty acid synthase; Elovl6, long-chain
elongase; Scd1, acyl-CoA desaturase 1; Gpam, glycerol-3-phosphate acyltransferase; Dgat1 and Dgat2, diacylglycerol acyltransferase 1 and 2; ChREBP,
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Narbohydrate-responsive element-binding protein; Srebp1, sterol regulat
lpha;  Ppara, Pparg and Ppard, peroxisome proliferator-activated recept
NA  fragmentation factor 45-like effectors (CIDEs) A, B, and C.
as carried out by one-way ANOVA with post hoc Dun-
ett’s  Multiple Comparisons Test where signiﬁcance was
ndicated. Differences with p < 0.05 were considered to be
igniﬁcant.  Statistical analyses were performed using Prism
.0  (GraphPad Software, Inc., La Jolla, CA, USA).. Results
Body weight did not change with CFE treatment, but
iver  weight normalized to body weight (relative liver
able 2
hanges in body weight, liver weight, plasma clinical parameters, and lipid conce
CFE-treated
Control (0%) 
Final body weight (g) 36.0 ± 0.93 [1.0] 
Liver  weight (% body weight) 4.33 ± 0.18 [1.0] 
Plasma clinical parameters
AST  (IU/L) 48.0 ± 7.5 [1.0] 
ALT  (IU/L) 17.0 ± 2.2 [1.0] 
ALP  (IU/L) 264 ± 35 [1.0] 
Plasma lipids
Triglyceride (mg/dL) 102 ± 19.0 [1.0] 
Cholesterol (mg/dL) 208 ± 9.6 [1.0] 
Phospholipid  (mg/dL) 277 ± 14.0 [1.0] 
Non-esteriﬁed  fatty acid (mequiv./L) 1.49 ± 0.39 [1.0] 
Hepatic  lipids
Triglyceride (mg/g liver) 14.1 ± 1.2 [1.0] 
Cholesterol (mg/g liver) 7.1 ± 0.51 [1.0] 
Phospholipid (mg/g liver) 13.9 ± 0.87 [1.0] 
ale ICR mice were maintained for 2 weeks on a diet supplemented with 0% CFE 
umbers  in brackets indicate the ratio compared to the control group.
* Signiﬁcant difference from the level of control group is indicated by p < 0.05.ent binding factor 1; Nr1h2 and Nr1h3, liver X receptor (LXR) beta and
a, gamma, and delta; Cidea, Cideb and Cidec/Fsp27, cell death–inducing
weight) increased in the 0.3% and 1% CFE groups. Hepatic
lipid  accumulation was  conﬁrmed by staining with Oil
Red  O. The liver tissue from the 0% CFE mice showed
no-remarkable change, but that from the 1% CFE mice
exhibited hepatic cellular damage, such as fatty change and
necrosis  (Fig. 1). Among the liver marker enzymes (AST,
ALT,  ALP) in plasma, ALP increased in the 1% CFE group;
while other enzymes appeared to be elevated by CFE treat-
ment,  those changes were not statistically signiﬁcant due
to  high standard error (Table 2). Plasma concentration of
ntration in plasma and liver of mice treated with CFE.
0.3% 1%
34.5 ± 0.46 [0.96] 33.6 ± 0.65 [0.93]
5.91 ± 0.27 [1.4]* 8.60 ± 0.40 [2.0]*
113.4 ± 32.6 [2.4] 160.0 ± 45.7 [3.3]
64.2 ± 21.3 [3.8] 100.6 ± 42.9 [5.9]
380 ± 72 [1.4] 512 ± 77 [1.9]*
99 ± 28.2 [1.0] 208 ± 34.6 [2.0]*
146 ± 24.3 [0.7] 189 ± 26.9 [0.9]
214 ± 31.6 [0.8] 268 ± 26.9 [1.0]
1.23 ± 0.37 [0.8] 1.85 ± 0.31 [1.2]
32.9 ± 2.7 [2.3]* 45.2 ± 4.9 [3.2]*
12.1 ± 1.5 [1.7]* 13.4 ± 1.1 [1.9]*
13.1 ± 1.1 [0.95] 13.4 ± 1.5 [0.97]
(control), 0.3% CFE, or 1% CFE. Each value is the mean and SE from 5 mice.
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e staine
% CFE.Fig. 1. Representative histopathologic changes in liver sections from mic
Mice  were maintained for 2 weeks on diet supplemented with 0, 0.3, or 1
triglycerides was increased in the 1% CFE group; plasma
levels of cholesterol, phospholipid, and non-esteriﬁed fatty
acid  were not changed by CFE exposure. Liver concentra-
tions of triglyceride and cholesterol were increased in the
0.3%  and 1% CFE groups; the increases in liver triglyceride
were 2.3- and 3.2-fold in the respective CFE-treated groups
compared with the control group.
Expression in the liver of mRNAs encoding lipid syn-
thesis enzymes and transcription factors was  analyzed.
Dose-related increases were detected in the levels of trans-
cripts  encoding various metabolic enzymes, especially
those for lipogenesis enzyme ACC2 and fatty acid elon-
gation enzyme Elovl6 (Fig. 2). Also, a clear increase was
observed in the levels of the mRNAs encoding transcription
factor PPAR and lipid droplet protein Fsp27 (Fig. 3).
4.  Discussion
As shown by our results, CFE treatment induced obvi-
ous  fatty liver even at the lower tested dose of 0.3% in the
diet.  The possible (non-exclusive) mechanisms of fatty liver
induction  include: (1) enhanced supply of non-esteriﬁed
fatty acid from adipose tissue, (2) reduced secretion
from liver, and (3) enhanced de novo lipogenesis. In an
attempt to distinguish these hypotheses, we examined the
possible  mechanism of action of fatty liver due to CFE
treatment.
An  overﬂow of fatty acid derived from lipolysis has
been proposed to be the main cause of the excess accu-
mulation of triglyceride observed in hepatic steatosis [23].
The  forskolin in CFE is thought to enhance lipolysis due to
activation  of adenylate cyclase [8,9]. Therefore, enhancedd with hematoxylin and eosin (H&E) and Oil red O (magniﬁcation 200×).
lipolysis by forskolin is implicated as a source of increased
fatty acid, leading to enhanced triglyceride synthesis in the
liver.  In fact, treatment of mice with 0.5% and 5% CFE for
3  weeks decreased fat tissue weight in our previous study
[13].  However, in the present study, non-esteriﬁed fatty
acid  in plasma was not enhanced by 0.3% CFE treatment
for 2 weeks, whereas a signiﬁcant increase in liver triglyc-
eride  concentration was  detected in this group. This ﬁnding
suggests that an overﬂow of fatty acid derived from lipoly-
sis  is unlikely to be the mechanism of CFE-induced hepatic
steatosis. Triglyceride is exported as lipoprotein from liver
into  blood. Reduced triglyceride secretion could lead to
accumulation of triglyceride in the liver, as observed in the
case  of CCl4 administration [18]. However, in the present
study, treatment with CFE did not yield a decrease in
plasma lipid concentration; plasma triglyceride was  rather
high  in 1% CFE group. This fact suggests that the effects of
CFE  exposure on fatty liver are not mediated by decreases
in  the secretion of liver triglycerides as in the case of CCl4
administration. Therefore, we  speculate that enhanced
de novo lipogenesis is involved in CFE-induced fatty
liver.
In  de novo lipogenesis, ACC and Fasn catalyze the rate-
limiting and ﬁnal steps, respectively [24]. Palmitoyl-CoA is
elongated  by Elovl6 and Scd1. Enzymes for triglyceride syn-
thesis  are transcriptionally regulated by ChREBP, SREBP-1c,
and  the LXRs (Nr1h2 and Nr1h3) in liver. ChREBP and
SREBP-1c induce ACC, Fasn, Elovl6, and Scd1 genes in
response to glucose and insulin, respectively. LXRs directly
and  indirectly activate transcription of the ACC-, Fasn-
,  and Scd1-encoding loci. In our present comprehensive
RT-PCR analysis, expression of mRNAs encoding enzymes
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tig. 2. Expression of mRNAs encoding enzymes involved in glycolysis, fa
rotein  product abbreviations are deﬁned in the main text and Table 1. Ea
ontrol  group (0% CFE) is indicated by *p < 0.05.nvolved in de novo synthesis of fatty acid and triglyceride
ere increased, especially those coding for ACC, Fasn, and
lovl6.  These changes in mRNA expression could contribute
o  enhance de novo lipogenesis due to CFE treatment,synthesis, chain elongation and desaturation, and triglyceride synthesis.
e is the mean and SE from 5 mice. Signiﬁcant difference from the level ofalthough mRNAs for the transcription factors themselves
did not show signiﬁcant accumulation.
Accumulating evidence suggests that nuclear receptor
PPARs, which consist of PPAR, PPAR, and PPAR, are
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nvolved
nce fromFig. 3. Expression of mRNAs encoding transcription factors and effectors i
abbreviations  are deﬁned in the main text and Table 1. Signiﬁcant differe
involved in lipid metabolism [25]. In the present study,
expression of the transcript encoding PPAR showed a clear
increase  in response to CFE treatment. PPAR is expressed
predominantly in adipose tissue, with low expression in
liver  [26], although this factor has been shown to play
a  critical role in hepatic steatosis in obese or diabetic
mouse models [27–29]. Among CIDE proteins, which are
involved in lipid droplet growth and lipoprotein lipida-
tion  [21], Fsp27/Cidec is an adipocyte lipid droplet protein
[30];  the Fsp27-encoding gene is directly regulated by
PPAR  in hepatic steatosis [28,31]. In the present study,
the  mRNAs for Fsp27/Cidec and for PPAR both accu-
mulated following exposure to CFE. On the other hand,
the  PPAR gene is expressed predominantly in the liver
and  is a major activator of fatty acid oxidation pathways; in fatty liver. Each values is the mean and SE from 5 mice. Protein product
 the level of control group (0% CFE) is indicated by *p < 0.05.
elevated PPAR activity leads to decreased lipid levels.
PPAR is ubiquitously expressed in many tissues and has
functions similar to those of PPAR. In the present study,
expression of the PPAR-encoding mRNA did not exhibit
change even at the higher tested dose of 1% CFE. Based on
these  ﬁndings, we  conclude that enhanced accumulation of
PPAR-  and Fsp27/Cidec-encoding transcripts might be a
major  contributor to CFE-induced fatty liver. Further detail
study  will be needed to conﬁrm expression of PPAR- and
Fsp27/Cidec at protein level.
CFE is a natural herbal product, and composition may
vary  among products. We  reported that two sources of CFE
standardized with 10% forskolin showed similar increases
in  relative liver weight and CYP induction [14]. Also,
we  observed that CFE treatment induced fatty liver and
logy Re
h
m
c
a
l
i
r
T
a
[
h
[
i
f
P
t
s
v
w
n
e
i
s
ﬁ
n
t
a
w
C
i
T
c
A
r
W
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[K. Umegaki et al. / Toxico
epatic CYP induction not only in ICR mice but also in C57BL
ice  (unpublished observation), suggesting fatty liver is
ommonly  induced by CFE. It will be critical to identify the
ctive  substance(s) involved in the CFE induction of fatty
iver.  Notably, forskolin itself appears not to be involved
n  CFE induction of fatty liver and CYP [13,14]. In ongoing
esearch, we are seeking to identify the active substance.
o date, we have shown that the substance is lipophilic,
s demonstrated by solubility in ether and ethyl acetate
15]. Drug metabolism and energy metabolism pathways
ave been shown to interface through nuclear receptors
32]. The present work suggests that the active substance
n  CFE affects the expression of the PPAR-encoding gene;
uture  work will need to examine how the accumulation of
PAR  message is related to CYP induction following CFE
reatment. It would be beneﬁcial to seek unidentiﬁed sub-
tance  by the expression of PPAR in studies in vivo and in
itro.
In  conclusion, this study indicated that CFE, a popular
eight-loss dietary supplement, induces fatty liver by de
ovo  lipogenesis, a process that may  be mediated through
nhanced expression of multiple enzymes and transcripts,
n  particular encoding PPAR and Fsp27. Previous work
uggested that fatty liver induction is the result of an unde-
ned  (non-forskolin) component of CFE. Thus, it will be
ecessary to identify unknown substance by focusing on
he  expression of PPAR and Fsp27, and eliminate this
ctivity from the extract to render CFE safe for use as a
eight-loss dietary supplement.
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